Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection — NEJM
1 Stefano Gitto, Nesrine Gamal, Pietro Andreone. . (2017) NS5A inhibitors for the treatment of hepatitis C infection. Journal of Viral Hepatitis 24:3, 180-186.



2 Wanyin Tao, Tianyu Gan, Jie Lu, Jin Zhong. . (2017) A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. Antiviral Research 139, 18-24.



3 Frank Tacke, Rainer Günther, Peter Buggisch, Hartwig Klinker, Andreas Schober, Christine John, Thomas Lutz, Heike Pfeiffer-Vornkahl, Claus Niederau, Markus Cornberg, Christoph Sarrazin, Stefan Mauss. . (2017) Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver International 37:2, 205-211.



4 C. Hézode. . (2017) Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions. Journal of Viral Hepatitis 24:2, 92-101.



5 Margaret Hellard, Alisa Pedrana, Nick Scott. . (2017) Targeted direct-acting antiviral treatment for chronic hepatitis C: A financial reality or an obstacle to elimination?. Journal of Hepatology 66:2, 270-272.



6 Samuel B. Ho, Alexander Monto, Adam Peyton, David E. Kaplan, Sean Byrne, Scott Moon, Amanda Copans, Lorenzo Rossaro, Anupma Roy, Hadley Le, Hadas Dvory-Sobol, Yanni Zhu, Diana M. Brainard, William Guyer, Obaid Shaikh, Michael Fuchs, Timothy R. Morgan, Geri Brown, Ramsey Cheung, Michael Fuchs, Bruce Gilliam, Sam Ho, Lennox Jeffers, David Kaplan, Joseph Lim, Alexander Monto, Timothy Morgan, Susanna Naggie, Prashant Pandya, Adam Peyton, David Rimland, Obaid Shaikh, Rohit Talwani, Boris Yoffee, Emily Cartwright. . (2017) Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. Clinical Gastroenterology and Hepatology 15:2, 282-288.



7 Suthat Liangpunsakul, Paul Y. Kwo. . (2017) Ushering in an Era Where No Group Who Wants to Be Treated Should Be Excluded. Clinical Gastroenterology and Hepatology 15:2, 289-291.



8 Delphine Degré, Thomas Sersté, Luc Lasser, Jean Delwaide, Peter Starkel, Wim Laleman, Philippe Langlet, Hendrik Reynaert, Stefan Bourgeois, Thomas Vanwolleghem, Sergio Negrin Dastis, Thierry Gustot, Anja Geerts, Christophe Van Steenkiste, Chantal de Galocsy, Antonia Lepida, Hans Orlent, Christophe Moreno, Ravi Jhaveri. . (2017) Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. PLOS ONE 12:1, e0170933.



9 Lucas A. Hill, David L. Wyles. . (2017) Future Paradigms of HCV Management with Resistance Testing. Current Hepatology Reports.



10 Daniel Todt, Bernhard Schlevogt, Katja Deterding, Adam Grundhoff, Michael P. Manns, Heiner Wedemeyer, Nicole Fischer, Markus Cornberg, Eike Steinmann. . (2017) Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir. Journal of Antimicrobial Chemotherapy, dkw572.



11 Yan A. Ivanenkov, Vladimir A. Aladinskiy, Nikolay A. Bushkov, Andrey A. Ayginin, Alexander G. Majouga, Alexandre V. Ivachtchenko. . (2017) Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015). Expert Opinion on Therapeutic Patents, 1-14.



12 Thomas R. McCarty, Joseph K. Lim. . (2017) Developing therapies to treat hepatitis C infection in post-liver transplant recipients. Expert Opinion on Pharmacotherapy, 1-10.



13 Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R. Foster, Antonio Craxí, Peter Buggisch, Faisal Sanai, Ceyhun Bicer, Oliver Lenz, Gino Van Dooren, Catherine Nalpas, Isabelle Lonjon-Domanec, Michael Schlag, Maria Buti, Jason Grebely. . (2017) Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLOS ONE 12:1, e0168713.



14 (2017) EASL Recommendations on Treatment of Hepatitis C 2016. Journal of Hepatology 66:1, 153-194.



15 Thomas Ward, Jason Gordon, Beverley Jones, Hayley Bennett, Samantha Webster, Anupama Kalsekar, Yong Yuan, Michael Brenner, Phil McEwan. . (2017) Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease. Clinical Drug Investigation 37:1, 61-70.



16 Elias B. Chahine, Allana J. Sucher, Brian A. Hemstreet. . (2017) Sofosbuvir/Velpatasvir. Annals of Pharmacotherapy 51:1, 44-53.



17 J. Llaneras, M. Riveiro-Barciela, M. Buti, R. Esteban. . (2017) Hepatitis C virus genotype 4: Genotype 1's little brother. Journal of Viral Hepatitis 24:1, 4-12.



18 Camilla S. Graham, Susanna Naggie, David P. Holland, Mark S. Sulkowski, David L. Thomas. . (2017) Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. Clinical Infectious Diseases 64:1, 92-99.



19 Tatsuo Kanda. . (2017) Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. Hepatology International 11:1, 38-44.



20 B. Khan, L. G. Singer, L. B. Lilly, C. Chaparro, T. Martinu, S. Juvet, M. Pipkin, T. K. Waddell, S. Keshavjee, A. Humar, M. Cypel. . (2017) Successful Lung Transplantation From Hepatitis C Positive Donor to Seronegative Recipient. American Journal of Transplantation.



21 Stefan Zeuzem, Masashi Mizokami, Stephen Pianko, Alessandra Mangia, Kwang-Hyub Han, Ross Martin, Evguenia Svarovskaia, Hadas Dvory-Sobol, Brian Doehle, Charlotte Hedskog, Chohee Yun, Diana M. Brainard, Steven Knox, John G. McHutchison, Michael D. Miller, Hongmei Mo, Wan-Long Chuang, Ira Jacobson, Gregory J. Dore, Mark Sulkowski. . (2017) NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus: Prevalence and Effect on Treatment Outcome. Journal of Hepatology.



22 Yvonne Chasser, Arthur Y. Kim, Oliver Freudenreich. . (2017) Hepatitis C Treatment: Clinical Issues for Psychiatrists in the Post-Interferon Era. Psychosomatics 58:1, 1-10.



23 M. Martinello, J. Grebely, K. Petoumenos, E. Gane, M. Hellard, D. Shaw, J. Sasadeusz, T. L. Applegate, G. J. Dore, G. V. Matthews. . (2017) HCV reinfection incidence among individuals treated for recent infection. Journal of Viral Hepatitis.



24 Jake A. Scott, Kara W. Chew. . (2016) Treatment optimization for HIV/HCV co-infected patients. Therapeutic Advances in Infectious Disease 163, 204993611668127.



25 Behzad Hajarizadeh, Jason Grebely, Marianne Martinello, Gail V Matthews, Andrew R Lloyd, Gregory J Dore. . (2016) Hepatitis C treatment as prevention: evidence, feasibility, and challenges. The Lancet Gastroenterology & Hepatology 1:4, 317-327.



26 Joël Gozlan. . (2016) Les nouveaux traitements de l’hépatite C. Revue Francophone des Laboratoires 2016:487, 65-73.



27 Elana S. Rosenthal, Camilla S. Graham. . (2016) Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infectious Agents and Cancer 11:1.



28 Marianne Martinello, Edward Gane, Margaret Hellard, Joe Sasadeusz, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Laurence Maire, Philippa Marks, Gregory J. Dore, Gail V. Matthews. . (2016) Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study. Hepatology 64:6, 1911-1921.



29 Daniel M. Forton. . (2016) How much of a problem is resistance in treating hepatitis C?. Current Opinion in Infectious Diseases 29:6, 625-631.



30 Marc Connelly, Michael G. Bruce, Lisa Bulkow, Mary Snowball, Brian J. McMahon. . (2016) The changing epidemiology and aetiology of hepatocellular carcinoma from 1969 through 2013 in Alaska Native people. Liver International 36:12, 1829-1835.



31 Jason Grebely, Gregory J. Dore, Stefan Zeuzem, Richard J. Aspinall, Raymond Fox, Lingling Han, John McNally, Anu Osinusi, Diana M. Brainard, G. Mani Subramanian, Macky Natha, Graham R. Foster, Alessandra Mangia, Mark Sulkowski, Jordan J. Feld. . (2016) Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. Clinical Infectious Diseases 63:11, 1479-1481.



32 Justin Taylor, Paula Cox-North, Charles S. Landis. . (2016) Management of Post-Liver Transplant Recurrence of Hepatitis C. Drugs 76:18, 1711-1717.



33 N. Kanaan, C. Raggi, E. Goffin, M. De Meyer, M. Mourad, M. Jadoul, C. Beguin, B. Kabamba, I. Borbath, Y. Pirson, Z. Hassoun. . (2016) Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation. Journal of Viral Hepatitis.



34 Barbara K. Dunn, Barnett S. Kramer. . (2016) Cancer Prevention: Lessons Learned and Future Directions. Trends in Cancer 2:12, 713-722.



35 Kevin Tin, Eiei Soe, James Park. . (2016) Management of Direct-Acting Antiviral Failures in Chronic Hepatitis C Infection. Current Hepatology Reports 15:4, 296-306.



36 Graham R Foster. . (2016) Chronic hepatitis C: less of a problem than first thought?. The Lancet Gastroenterology & Hepatology.



37 Neil D. Shah, Michael W. Fried. . (2016) Opciones terapéuticas para los pacientes con hepatitis C crónica y fracaso terapéutico previo. Clinical Liver Disease 8:S1, S25-S29.



38 Steven L. Flamm. . (2016) Velpatasvir y sofosbuvir: ¿Por qué utilizar un fármaco nuevo si los antiguos funcionan bien?. Clinical Liver Disease 8:S1, S16-S19.



39 Edward J. Gane, Kris V. Kowdley, David Pound, Catherine A.M. Stedman, Mitchell Davis, Kyle Etzkorn, Stuart C. Gordon, David Bernstein, Gregory Everson, Maribel Rodriguez-Torres, Naoky Tsai, Omer Khalid, Jenny C. Yang, Sophia Lu, Hadas Dvory-Sobol, Luisa M. Stamm, Diana M. Brainard, John G. McHutchison, Myron Tong, Raymond T. Chung, Kimberly Beavers, John E. Poulos, Paul Y. Kwo, Mindie H. Nguyen. . (2016) Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. Gastroenterology 151:5, 902-909.



40 Sarah Herold, Oliver Freudenreich. . (2016) Hepatitis C Virus and Schizophrenia: Expanding the Role of the Community Psychiatrist. Psychosomatics 57:6, 634-637.



41 Lize Cuypers, Francesca Ceccherini-Silberstein, Kristel Van Laethem, Guangdi Li, Anne-Mieke Vandamme, Jürgen Kurt Rockstroh. . (2016) Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Reviews in Medical Virology 26:6, 408-434.



42 Eric Lawitz, Nancy Reau, Federico Hinestrosa, Mordechai Rabinovitz, Eugene Schiff, Aasim Sheikh, Ziad Younes, Robert Herring, K. Rajender Reddy, Tram Tran, Michael Bennett, Ronald Nahass, Jenny C. Yang, Sophia Lu, Hadas Dvory-Sobol, Luisa M. Stamm, Diana M. Brainard, John G. McHutchison, Brian Pearlman, Mitchell Shiffman, Trevor Hawkins, Michael Curry, Ira Jacobson. . (2016) Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology 151:5, 893-901.e1.



43 Alessio Aghemo, Maria Buti. . (2016) Hepatitis C Therapy: Game Over!. Gastroenterology 151:5, 795-798.



44 Lucas A. Hill, David L. Wyles. . (2016) Emerging complexities with hepatitis C virus direct-acting antiviral regimens: Less is still Way more. Hepatology 64:5, 1401-1403.



45 Anita Kohli, Ali Alshati, Fawaz Georgie, Richard Manch, Robert G. Gish. . (2016) Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. Therapeutic Advances in Gastroenterology 9:6, 887-897.



46 Zobair M. Younossi, Maria Stepanova, Jordon Feld, Stefan Zeuzem, Mark Sulkowski, Graham R. Foster, Alessandra Mangia, Michael Charlton, Jacqueline G. O’Leary, Michael P. Curry, Fatema Nader, Linda Henry, Sharon Hunt. . (2016) Sofosbuvir and Velpatasvir Combination Improves Outcomes Reported by Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology.



47 John J. Faragon. . (2016) Drug Interactions Associated with HIV and HCV Medications. Current Treatment Options in Infectious Diseases.



48 Ana I. de Ávila, Isabel Gallego, Maria Eugenia Soria, Josep Gregori, Josep Quer, Juan Ignacio Esteban, Charles M. Rice, Esteban Domingo, Celia Perales, Ming-Lung Yu. . (2016) Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. PLOS ONE 11:10, e0164691.



49 Mohamed B. Hashem, Tamer Elbaz, Mohamed El-kassas, Gamal Esmat. . (2016) Management of Hepatitis C Virus—Genotypes 4, 5, and 6 Using Direct Antiviral Agents: Review of Current Status. Current Treatment Options in Infectious Diseases.



50 Guglielmo Borgia, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, Riccardo Scotto, Ivan Gentile. . (2016) The therapeutic potential of new investigational hepatitis C virus translation inhibitors. Expert Opinion on Investigational Drugs 25:10, 1209-1214.



51 Isabella Esposito, Julieta Trinks, Vicente Soriano. . (2016) Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opinion on Drug Metabolism & Toxicology 12:10, 1197-1209.



52 Sarah L. Greig. . (2016) Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C. Drugs 76:16, 1567-1578.



53 Armand Abergel, Sophie Metivier, Didier Samuel, Deyuan Jiang, Kathryn Kersey, Phillip S. Pang, Evguenia Svarovskaia, Steven J. Knox, Veronique Loustaud-Ratti, Tarik Asselah. . (2016) Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 64:4, 1049-1056.



54 S. Lanini, P.J. Easterbrook, A. Zumla, G. Ippolito. . (2016) Hepatitis C: global epidemiology and strategies for control. Clinical Microbiology and Infection 22:10, 833-838.



55 Rudruidee Karnchanasorn, Horng-Yih Ou, James Lin, Lee-Ming Chuang, Ken C. Chiu. . (2016) Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination. Current Diabetes Reports 16:10.



56 V. L. Ferreira, N. A. Assis Jarek, F. S. Tonin, H. H. L. Borba, A. Wiens, R. Pontarolo. . (2016) Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. Journal of Clinical Pharmacy and Therapeutics 41:5, 478-485.



57 Markus Cornberg, Michael P Manns. . (2016) Hepatitis C: individualised medicine versus one pill fits all. The Lancet Gastroenterology & Hepatology 1:2, 86-87.



58 Darius Moradpour, Arash Grakoui, Michael P. Manns. . (2016) Future landscape of hepatitis C research – Basic, translational and clinical perspectives. Journal of Hepatology 65:1, S143-S155.



59 Jens Bukh. . (2016) The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. Journal of Hepatology 65:1, S2-S21.



60 Jordan J. Feld, Graham R. Foster. . (2016) Second generation direct-acting antivirals – Do we expect major improvements?. Journal of Hepatology 65:1, S130-S142.



61 J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman. . (2016) Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clinical Microbiology and Infection 22:10, 846-852.



62 Zobair M. Younossi, Aybike Birerdinc, Linda Henry. . (2016) Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. Journal of Hepatology 65:1, S109-S119.



63 Pratichi Singh, J. Febin Prabhu Dass. . (2016) A multifaceted computational report on the variants effect on KIR2DL3 and IFNL3 candidate gene in HCV clearance. Molecular Biology Reports 43:10, 1101-1117.



64 F Wiesmann, P Braun. . (2016) Significance of HCV RNA monitoring in the era of new potent therapies. Expert Review of Anti-infective Therapy 14:9, 837-844.



65 Jonas Schreiber, John McNally, Krishna Chodavarapu, Evguenia Svarovskaia, Christophe Moreno. . (2016) Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir. Hepatology 64:3, 983-985.



66 Monique R. Bidell, Milena McLaughlin, John Faragon, Caroline Morse, Nimish Patel. . (2016) Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. Infectious Diseases and Therapy 5:3, 299-312.



67 Imam Waked, Gamal Shiha, Roula B Qaqish, Gamal Esmat, Ayman Yosry, Mohamed Hassany, Reham Soliman, Mohammad A Mohey, Naglaa Allam, Naglaa Zayed, Tarik Asselah, Coleen Hall, Rebecca Redman, Niloufar Mobashery, Wahid Doss. . (2016) Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. The Lancet Gastroenterology & Hepatology 1:1, 36-44.



68 L. T. Padua, R. Jhaveri. . (2016) Hepatitis C Mother-to-Child Transmission. NeoReviews 17:9, e521-e531.



69 M. Elaine Eyster, Lan Kong, Menghan Li, Ian R. Schreibman. . (2016) Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort. American Journal of Hematology 91:9, E335-E340.



70 Silvia Vilarinho, Richard P. Lifton. . (2016) Pioneering a Global Cure for Chronic Hepatitis C Virus Infection. Cell 167:1, 12-15.



71 Tarik Asselah, Christophe Hézode, Roula B Qaqish, Magdy ElKhashab, Tarek Hassanein, George Papatheodoridis, Jordan J Feld, Christophe Moreno, Stefan Zeuzem, Peter Ferenci, Yao Yu, Rebecca Redman, Tami Pilot-Matias, Niloufar Mobashery. . (2016) Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. The Lancet Gastroenterology & Hepatology 1:1, 25-35.



72 Dennis J. Cada, Anne P. Kim, Danial E. Baker. . (2016) Elbasvir/Grazoprevir. Hospital Pharmacy 51:8, 665-686.



73 Shruti H. Mehta, Allison M. McFall, Aylur K. Srikrishnan, M. Suresh Kumar, Paneerselvam Nandagopal, Javier Cepeda, David L. Thomas, Mark S. Sulkowski, Sunil S. Solomon. . (2016) Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India. Open Forum Infectious Diseases 3:3, ofw121.



74 Edward J. Gane, Christian Schwabe, Robert H. Hyland, Yin Yang, Evguenia Svarovskaia, Luisa M. Stamm, Diana M. Brainard, John G. McHutchison, Catherine A. Stedman. . (2016) Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections. Gastroenterology 151:3, 448-456.e1.



75 Surasak Jittavisutthikul, Watee Seesuay, Jeeraphong Thanongsaksrikul, Kanyarat Thueng-in, Potjanee Srimanote, Rolf G. Werner, Wanpen Chaicumpa. . (2016) Human Transbodies to HCV NS3/4A Protease Inhibit Viral Replication and Restore Host Innate Immunity. Frontiers in Immunology 7.



76 Nicholas A. Meanwell. . (2016) 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. Journal of Medicinal Chemistry 59:16, 7311-7351.



77 Seyed Moayed Alavian, Behzad Hajarizadeh, Kamran Bagheri Lankarani, Heidar Sharafi, Nasser Ebrahimi Daryani, Shahin Merat, Minoo Mohraz, Masoud Mardani, Mohamad Reza Fattahi, Hossein Poustchi, Mehri Nikbin, Mahmood Nabavi, Peyman Adibi, Masood Ziaee, Bita Behnava, Mohammad Saeid Rezaee-Zavareh, Massimo Colombo, Hatef Massoumi, Abdul Rahman Bizri, Bijan Eghtesad, Majid Amiri, Ali Namvar, Khashayar Hesamizadeh, Reza Malekzadeh. . (2016) Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepatitis Monthly 16:8.



78 Franco Dammacco, Vito Racanelli, Sabino Russi, Domenico Sansonno. . (2016) The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review. Clinical and Experimental Medicine 16:3, 233-242.



79 M. Ladino, F. Pedraza, D. Roth. . (2016) Hepatitis C Virus Infection in Chronic Kidney Disease. Journal of the American Society of Nephrology 27:8, 2238-2246.



80 Heather Y. Hughes, David K. Henderson. . (2016) Postexposure prophylaxis after hepatitis C occupational exposure in the interferon-free era. Current Opinion in Infectious Diseases 29:4, 373-380.



81 Steven L. Flamm. . (2016) Velpatasvir and sofosbuvir: How will we use a new drug when the old agents work well?. Clinical Liver Disease 8:2, 39-42.



82 Chia-Yu Liu, Pin-Hao Ko, Hung-Rong Yen, Chen-Hung Cheng, Yu-Hsien Li, Zih-Han Liao, Chung-Hua Hsu. . (2016) The Chinese medicine Kuan-Sin-Yin improves liver function in patients with chronic hepatitis C: A randomised and placebo-controlled trial. Complementary Therapies in Medicine 27, 114-122.



83 Kittirat Glab-ampai, Aijaz Ahmad Malik, Monrat Chulanetra, Jeeraphong Thanongsaksrikul, Kanyarat Thueng-in, Potjanee Srimanote, Pongsri Tongtawe, Wanpen Chaicumpa. . (2016) Inhibition of HCV replication by humanized-single domain transbodies to NS4B. Biochemical and Biophysical Research Communications 476:4, 654-664.



84 Michael Charlton, Travis Dick. . 2016. Hepatitis C. Practical Gastroenterology and Hepatology Board Review Toolkit, 480-486.



85 Christine E. MacBrayne, Jennifer J. Kiser. . (2016) Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV. Clinical Infectious Diseases 63:suppl 1, S12-S23.



86 Mark W. Hull, Eric M. Yoshida, Julio S. G. Montaner. . (2016) Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. Current Infectious Disease Reports 18:7.



87 Jean-Michel Pawlotsky. . (2016) Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology 151:1, 70-86.



88 Zobair M. Younossi, Maria Stepanova, Jordan Feld, Stefan Zeuzem, Ira Jacobson, Kosh Agarwal, Christophe Hezode, Fatema Nader, Linda Henry, Sharon Hunt. . (2016) Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. Journal of Hepatology 65:1, 33-39.



89 Elise J. Smolders, Clara T. M. M. de Kanter, Bart van Hoek, Joop E. Arends, Joost P. H. Drenth, David M. Burger. . (2016) Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. Drug Safety 39:7, 589-611.



90 Claire F. Friedman, Jedd D. Wolchok. . (2016) Patient-Physician Communication in the 21st Century. Trends in Immunology 37:6, 347-349.



91 Johannes Wiegand, Florian van Bömmel, Andrés Duarte-Rojo, José Altamirano, Juan G. Abraldes, Augusto Villanueva, Thomas Berg. . (2016) Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015. Journal of Hepatology 64:6, 1428-1445.



92 A. Majumdar, M. T. Kitson, S. K. Roberts. . (2016) Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Alimentary Pharmacology & Therapeutics 43:12, 1276-1292.



93 Daniel J Felmlee, Audrey Coilly, Raymond T Chung, Didier Samuel, Thomas F Baumert. . (2016) New perspectives for preventing hepatitis C virus liver graft infection. The Lancet Infectious Diseases 16:6, 735-745.



94 Matthias Götte, Jordan J. Feld. . (2016) Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nature Reviews Gastroenterology & Hepatology 13:6, 338-351.



95 Ivan Gentile, Riccardo Scotto, Emanuela Zappulo, Antonio Riccardo Buonomo, Biagio Pinchera, Guglielmo Borgia. . (2016) Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opinion on Investigational Drugs 25:5, 557-572.



96 Thierno Diatta, Delphine Chavade, Françoise Degos, Anne d’Andon, Loïc Guillevin. . (2016) Infection par le virus de l’hépatite C : prise en charge thérapeutique. La Presse Médicale 45:5, 495-508.



97 Fabrizio Fabrizi, Paul Martin, Piergiorgio Messa. . (2016) New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney International 89:5, 988-994.



98 (2016) Sofosbuvir and Velpatasvir for Patients with HCV Infection. New England Journal of Medicine 374:17, 1687-1689.



99 Jay H. Hoofnagle. . (2016) Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. Journal of Hepatology 64:4, 763-765.



100 Antonio Rivero-Juárez, Antonio Rivero. . (2016) Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5. The Lancet Infectious Diseases 16:4, 392-393.



101 Massimo Puoti, Roberto Rossotti, Chiara Baiguera, Maurizio Orso. . (2016) Treatment of hepatitis C virus genotype 1-infected patients: mission accomplished?. Liver International 36:2, 181-184.



102 Neil D. Shah, Michael W. Fried. . (2016) Treatment options of patients with chronic hepatitis C who have failed prior therapy. Clinical Liver Disease 7:2, 40-44.



103 Dirk Einecke. . (2016) Neue Kombination heilt noch mehr Patienten in noch kürzerer Zeit. MMW - Fortschritte der Medizin 158:3, 14-14.



104 Cari Coscia, Ernest Saxton, Sharon Dickinson. . (2016) Postoperative Care of a Liver Transplant Recipient Using a Classification System. Critical Care Nursing Quarterly 39:3, 252-266.



105 Franco Dammacco, Sabino Russi, Domenico Sansonno. . 2016. HCV-Related Cryoglobulinemic Vasculitis: An Overview. Systemic Vasculitides: Current Status and Perspectives, 333-344.



106 Nicolas Goossens, Sophie Clément, Francesco Negro. . 2016. Management of HCV Infection. Handbook of Hepatitis C, 61-78.



107 Akihiro Tamori, Masaru Enomoto, Norifumi Kawada. . (2016) Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators of Inflammation 2016, 1-11.



108 Sang Hoon Park. . (2016) Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1. The Korean Journal of Gastroenterology 67:3, 127.



109 Ki Tae Yoon. . (2016) Direct Acting Antivirals Which Is Effective in Pan-genotypic Chronic Hepatitis C Patients with or without Liver Cirrhosis. The Korean Journal of Gastroenterology 68:4, 229.



110 Curry, Michael P., O’Leary, Jacqueline G., Bzowej, Natalie, Muir, Andrew J., Korenblat, Kevin M., Fenkel, Jonathan M., Reddy, K. Rajender, Lawitz, Eric, Flamm, Steven L., Schiano, Thomas, Teperman, Lewis, Fontana, Robert, Schiff, Eugene, Fried, Michael, Doehle, Brian, An, Di, McNally, John, Osinusi, Anu, Brainard, Diana M., McHutchison, John G., Brown, Robert S. Jr., Charlton, Michael, . . (2015) Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. New England Journal of Medicine 373:27, 2618-2628.



111 Ward, John W., Mermin, Jonathan H., . . (2015) Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs. New England Journal of Medicine 373:27, 2678-2680.